Goldman Sachs Boosts BioNTech SE Outlook to ‘Buy’
Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE – Depositary Receipt () (XTRA:22UA) from Neutral to Buy.
Analyst Price Forecast Points to 23.81% Upside Potential
As of October 22, 2024, analysts have set the average one-year price target for BioNTech SE – Depositary Receipt () at 122.63 €/share. This range of forecasts stretches from a low of 82.55 € to a high of 163.05 €. The average price target indicates a potential rise of 23.81% from its latest closing price of 99.05 €/share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for BioNTech SE – Depositary Receipt () stands at 3,963 million, representing a promising increase of 30.36%. Expected annual non-GAAP EPS is estimated at 2.77.
Investor Sentiment Towards the Company
A total of 396 funds or institutions are reporting positions in BioNTech SE – Depositary Receipt (). This marks a minor increase of 1 owner or 0.25% in the last quarter. The average portfolio weight of all funds holding 22UA is 0.27%, which has grown by 9.20%. Institutions saw a decrease of 3.33% in total shares owned over the past three months, bringing the total down to 47,671K shares.
Recent Actions by Major Shareholders
Baillie Gifford holds 8,308K shares, a modest increase from the 8,276K shares reported previously, which translates to an increase of 0.38%. However, the firm reduced its portfolio allocation in 22UA by 46.42% this last quarter.
Primecap Management owns 4,517K shares, down from 4,790K shares previously, indicating a decrease of 6.04%. Despite this, the firm’s portfolio allocation in 22UA increased by 41.54% quarter-over-quarter.
Flossbach Von Storch has 4,360K shares. Previously, they reported owning 4,379K shares, marking a decrease of 0.46%. Nonetheless, they increased their portfolio allocation in 22UA by 37.66% over the recent quarter.
Harding Loevner decreased its holdings from 3,818K shares to 2,927K shares, which is a decrease of 30.46%. The firm’s portfolio allocation in 22UA fell by 40.28% this past quarter.
VHCOX – Vanguard Capital Opportunity Fund Investor Shares has seen an increase in shares, holding 2,372K shares compared to 2,357K shares reported previously, reflecting an increase of 0.65%. Their portfolio allocation in 22UA decreased by 14.07% over the last quarter.
Fintel is a notable platform providing extensive investment research for individual investors, traders, financial advisors, and small hedge funds. Our data includes fundamentals, analyst reports, ownership data, fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
